Compumedics Limited (CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany-based DWL Elektronishe Systeme GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.
Find out what a historical investment in Compumedics would be worth today using our CMP stock calculator.
Buying CMP shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Compumedics in minutes.
Sign up with some I.D. and zero paperwork
Add funds to your account
Make your first investment in CMP
What is the ticker symbol of Compumedics?
The ticker symbol for Compumedics is CMP.
How much is one share of CMP?
One share of CMP is valued at $0.24 as of 20 November 2026.
What is the market capitalisation of Compumedics CMP?
As of 20 November 2026 Compumedics has a market cap of $46.94M.
What is the P/E ratio of CMP?
The Price to Earnings ratio of CMP is 180.77.
What is the Earnings Per Share of CMP?
The Earnings Per Share of CMP is $0.00.
What is the 52-week high for Compumedics stock?
The Compumedics 52-week high stock price is $0.45.
What is the 52-week low for Compumedics stock?
The Compumedics 52-week low stock price is $0.22.
Can I buy CMP shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy CMP shares and over 13,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.